INO - Inovio Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.6201
+0.0002 (+0.03%)
At close: 04:00PM EDT
0.6200 -0.00 (-0.02%)
After hours: 07:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Hammer

Hammer

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.6199
Open0.6132
Bid0.6142 x 3000
Ask0.6200 x 1100
Day's Range0.5950 - 0.6208
52 Week Range0.5800 - 2.8200
Volume5,058,504
Avg. Volume6,267,037
Market Cap162.925M
Beta (5Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)-0.9700
Earnings DateAug 07, 2023 - Aug 11, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PR Newswire

    INOVIO to Present at the 2023 Jefferies Healthcare Conference

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO, and Dr. Michael Sumner, CMO, will present at the 2023 Jefferies Healthcare Conference.

  • PR Newswire

    INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

    INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company's product candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP). INO-3107 is an investigational DNA medicine candidate designed to elicit a targeted T cell response against H

  • Zacks

    All You Need to Know About Inovio (INO) Rating Upgrade to Buy

    Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • Simply Wall St.

    These Analysts Think Inovio Pharmaceuticals, Inc.'s (NASDAQ:INO) Sales Are Under Threat

    The analysts covering Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) delivered a dose of negativity to shareholders today...

  • Simply Wall St.

    Analysts Have Lowered Expectations For Inovio Pharmaceuticals, Inc. (NASDAQ:INO) After Its Latest Results

    As you might know, Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) last week released its latest first-quarter, and things...

  • Simply Wall St.

    Inovio Pharmaceuticals First Quarter 2023 Earnings: Misses Expectations

    Inovio Pharmaceuticals ( NASDAQ:INO ) First Quarter 2023 Results Key Financial Results Revenue: US$114.9k (down 42...

  • Motley Fool

    Inovio Pharmaceuticals (INO) Q1 2023 Earnings Call Transcript

    Good afternoon and thank you for joining the Inovio 2023 first quarter conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO; Dr. Michael Sumner, chief medical officer; and Mr.

  • Zacks

    Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

    Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights

    INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced financial results and operational highlights for the first quarter of 2023. INOVIO's management will host its quarterly conference call and webcast today at 4:30 p.m. EDT. The live webcast and replay may be accessed by visiting INOVIO's website at http://ir.inovio.com/events-and-presentati

  • PR Newswire

    New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Me

  • PR Newswire

    INOVIO to Present at the 2023 RBC Capital Markets Global Healthcare Conference

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the 2023 RBC Capital Markets Global Healthcare Conference.

  • PR Newswire

    INOVIO to Report First Quarter 2023 Financial Results on May 10, 2023

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

  • PR Newswire

    INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis at COSM 2023

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for oral presentation on INO-3107 for the treatment of Recurrent Respiratory Papillomatosis (RRP) at this year's American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts

  • PR Newswire

    European Committee for Orphan Medicinal Products Provides Positive Opinion on INOVIO's Application for Orphan Drug Designation for INO-3107

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Committee for Orphan Medicinal Products (COMP) has provided a positive opinion on INOVIO's application for orphan drug designation in the European Union (EU) for INO-3107. INO-3107 is the company's product candidate that may contribute to the treatment of Recurrent Respi

  • Motley Fool

    These 3 Nasdaq Stocks Are on Fire Today: Here's Why

    What happened Biopharmaceutical stocks were trending higher across the board Monday morning, thanks to Merck's (NYSE: MRK) nearly $11 billion buyout offer for Prometheus Biosciences (NASDAQ: RXDX). So far, some of the day's biggest winners have been the cancer immunotherapy specialist Agenus (NASDAQ: AGEN), the next-generation vaccine player Inovio Pharmaceuticals (NASDAQ: INO), and the drug developer Roivant Sciences (NASDAQ: ROIV).

  • PR Newswire

    Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that data from a Phase 1b trial evaluating INO-4201 as an Ebola booster vaccine candidate for rVSV-ZEBOV (Ervebo) (NCT04906629) was presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Dr. Angela Huttner, Infectious Disease Consultant, Gene

  • Motley Fool

    Why Inovio Pharmaceuticals' Shares Jumped on Thursday

    Shares of Inovio Pharmaceuticals (NASDAQ: INO) were up 20% early Thursday afternoon after the biotech company announced that it will present its abstract for INO-4201 as an Ebola booster for rVSV-ZEBOV (Ervebo) at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on Sunday. Inovio mainly focuses on DNA medicines to treat people with human papillomavirus (HPV) diseases, cancer, and infectious diseases. The main concern with Inovio is the company lost $279.8 million last year and says it has only enough cash -- $253 million -- to last into the first quarter of 2025.

  • PR Newswire

    INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023

    INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that an abstract has been accepted for presentation for INO-4201 as an Ebola booster for rVSV-ZEBOV (Ervebo) at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

  • Motley Fool

    Why Shares of Inovio Pharmaceuticals Were Down Tuesday

    Shares of Inovio Pharmaceuticals (NASDAQ: INO) were down more than 10% on Tuesday afternoon, falling to a 52-week low of $0.07036 a share at one point. The biotechnology company specializes in developing DNA medicines to treat people with human papillomavirus (HPV) diseases, cancer, and infectious diseases. When the company announced on Monday that it was offering Dr. Cheryl Elder, its newly hired senior vice president for regulatory affairs, stock options under its 2022 Inducement Plan, the stock dropped again.

  • PR Newswire

    INOVIO Reports Inducement Grant Under Inducement Plan

    INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to its newly hired Senior Vice President, Regulatory Affairs under its 2022 Inducement Plan (the "Inducement Plan").

  • Insider Monkey

    Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Call Transcript

    Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Good afternoon, and welcome to the Inovio Pharmaceuticals Fourth Quarter 2022 Financial Results Conference Call. Please note, this event is being recorded. I would now like to turn the conference over to Thomas Hong, Manager of Investor Relations. Please go ahead. Thomas […]

  • PR Newswire

    INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

    INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D., President and CEO, will present at the Oppenheimer 33rd Annual Healthcare Conference.

  • Motley Fool

    Inovio Pharmaceuticals (INO) Q4 2022 Earnings Call Transcript

    Good afternoon, and thank you for joining the Inovio 2022 fourth quarter and full year financial results conference call. Joining me on today's call are Dr. Jackie Shea, president and CEO and Dr. Michael Sumner, chief medical officer; and Mr. Today's call will review our corporate and financial information for the quarter and year ended December 31st, 2022, as well as provide an update on our efforts to develop our DNA medicines platform.

  • Zacks

    Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates

    Inovio (INO) delivered earnings and revenue surprises of -31.25% and 72.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights

    INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today reported financial results for the quarter and year ended December 31, 2022, and provided a business update. INOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. Eastern Time today to discuss financial results and provide a general business update for the fourth